R. Andrew Sewell, MD

Printer-friendly version

Associate research scientist, VA Connecticut Healthcare, Yale University School of Medicine

Latuda: “Procognitive” or Pro-Profit? [Subscribers Only]

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?